A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition

por Arulraj, Theinmozhi, Wang, Hanwen, Emens, Leisha A., Santa-Maria, Cesar A., Popel, Aleksander S.
Publicado 2023

Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer

por Wang, Hanwen, Zhao, Chen, Santa-Maria, Cesar A., Emens, Leisha A., Popel, Aleksander S.
Publicado 2022

Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

por Cheng, Joyce M., Canzoniero, Jenna, Lee, Seoho, Soni, Sudeep, Mangini, Neha, Santa-Maria, Cesar A.
Publicado 2023

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy

por Talamantes, Sarah, Xie, Eric, Costa, Ricardo L. B., Chen, Melissa, Rademaker, Alfred, Santa‐Maria, Cesar A.
Publicado 2020

Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer

por Tolba, Mai F., Santa-Maria, Cesar A., Albini, Adriana, Chimusa, Emile R., Al-Ramadi, Basel K., Tolaney, Sara M.
Publicado 2021

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

por Wang, Hanwen, Milberg, Oleg, Bartelink, Imke H., Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Santa-Maria, Cesar A., Popel, Aleksander S.
Publicado 2019

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

por Costa, Ricardo, Santa-Maria, Cesar A, Rossi, Giovanna, Carneiro, Benedito A, Chae, Young Kwang, Gradishar, William J, Giles, Francis J, Cristofanilli, Massimo
Publicado 2016

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

por Shah, Ami N, Flaum, Lisa, Helenowski, Irene, Santa-Maria, Cesar A, Jain, Sarika, Rademaker, Alfred, Nelson, Valerie, Tsarwhas, Dean, Cristofanilli, Massimo, Gradishar, William
Publicado 2020

Genomic landscape of DNA repair genes in cancer

por Chae, Young Kwang, Anker, Jonathan F., Carneiro, Benedito A., Chandra, Sunandana, Kaplan, Jason, Kalyan, Aparna, Santa-Maria, Cesar A., Platanias, Leonidas C., Giles, Francis J.
Publicado 2016

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

por Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Publicado 2022

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

por Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Publicado 2022

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

por Naidoo, Jarushka, Schreck, Karisa C, Fu, Wei, Hu, Chen, Carvajal-Gonzalez, Alexander, Connolly, Roisin M, Santa-Maria, Cesar A, Lipson, Evan J, Holdhoff, Matthias, Forde, Patrick M, Douville, Christopher, Riemer, Joanne, Barnes, Amanda, Redmond, Kristin J, Kleinberg, Lawrence, Page, Brandi, Aygun, Nafi, Kinzler, Kenneth W, Papadopoulos, Nickolas, Bettegowda, Chetan, Venkatesan, Arun, Brahmer, Julie R, Grossman, Stuart A
Publicado 2021

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

por Ademuyiwa, Foluso O., Gao, Feng, Street, Cherease R., Chen, Ina, Northfelt, Donald W., Wesolowski, Robert, Arora, Mili, Brufsky, Adam, Dees, E. Claire, Santa-Maria, Cesar A., Connolly, Roisin M., Force, Jeremy, Moreno-Aspitia, Alvaro, Herndon, John M., Carmody, Madelyn, Davies, Sherri R., Larson, Sarah, Pfaff, Kathleen L., Jones, Stephanie M., Weirather, Jason L., Giobbie-Hurder, Anita, Rodig, Scott J., Liu, Zheng, Hagemann, Ian S., Sharon, Elad, Gillanders, William E.
Publicado 2022

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

por Luke, Jason J., Patel, Manish R., Blumenschein, George R., Hamilton, Erika, Chmielowski, Bartosz, Ulahannan, Susanna V., Connolly, Roisin M., Santa-Maria, Cesar A., Wang, Jie, Bahadur, Shakeela W., Weickhardt, Andrew, Asch, Adam S., Mallesara, Girish, Clingan, Philip, Dlugosz-Danecka, Monika, Tomaszewska-Kiecana, Monika, Pylypenko, Halyna, Hamad, Nada, Kindler, Hedy L., Sumrow, Bradley J., Kaminker, Patrick, Chen, Francine Z., Zhang, Xiaoyu, Shah, Kalpana, Smith, Douglas H., De Costa, Anushka, Li, Jonathan, Li, Hua, Sun, Jichao, Moore, Paul A.
Publicado 2023